The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) opened last Monday its 19th Annual European Congress in Vienna, Austria with a plenary session entitled What Synergies Could Be Created Between Regulatory and Health Technology Assessments?The plenary discussion was moderated by

Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016 Update on Lung Cancers, plus selected highlights in other tumours  Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA NSCLC AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II